PR Newswire All News ReleasesCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 09:03:00·⟳ 抓取 09:03:13 +13s·⚡ 决策 09-01 09:04:39 +1m26s·56.5 天前
Rosen律所提醒Capricor证券集体诉讼首席原告截止日,未提供新增经营或监管事实
本信号不是新的监管或经营结果,而是已知证券诉讼的律所提醒;对Capricor Therapeutics(CAPR.US)没有可量化新增基本面冲击,也无法形成新的做空edge。
📄 原文PR Newswire All News Releases↗ 原文
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of s…
不做 Capricor Therapeutics, Inc.(CAPR.US)
不做:Rosen公告只是已知证券集体诉讼的首席原告期限提醒,未新增FDA、法院、赔偿或经营事实,7月核心负面已充分传播并重定价。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Rosen公告重复了Capricor Deramiocel BLA统计分析争议、FDA AdCom负面投票和证券诉讼指控;这些核心事实已在7月27日FDA简报、7月29日AdCom/公司8-K、7月30日证券诉讼及公司10-Q中进入市场。本条只增加9月28日首席原告截止日提醒,不改变收入、审批概率、诉讼阶段或赔偿量级,因此不做。
消息传播链
- 公司公告FDA咨询委员会以3票赞成、9票反对认为现有证据不支持Deramiocel治疗DMD相关心肌病疗效,构成诉讼指控的核心监管背景。
- 公司10-Q披露2026-07-30已有针对Capricor及部分高管的证券集体诉讼,说明本条Rosen提醒不是诉讼首次出现。
- 另一律所已在Rosen公告前提醒同一9月28日首席原告截止日,并复述7月FDA文件和AdCom导致股价下跌。
- Rosen发布投资者招募和首席原告期限提醒,但未披露新的法院裁定、赔偿金额或FDA进展。市场反应:CAPR.US 8月31日常规交易收于9.91美元,盘后小幅至9.86美元;该提醒发布在美股盘后。
关键理由
- 本条仅为证券集体诉讼首席原告期限提醒,不是新的FDA决定、法院裁定或公司经营披露。
- 量级无法形成新增交易边际:公司10-Q已披露相关诉讼且截至2026-06-30未记录重大或有损失准备,本条未披露赔偿金额或新负债。
- 股价主要重定价已发生在7月FDA简报和AdCom负面投票后,当前提醒对CAPR.US新增信息含量低。
主要风险
- 若后续法院驳回动议失败、出现实质赔偿金额或FDA正式拒批/批准,需重新评估CAPR.US方向。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08 · 影响 weakens
公司10-Q已披露证券诉讼,Rosen提醒没有新增法院进展或赔偿金额,削弱基于本条开空的边际。
检索:Capricor Therapeutics CAPR class action lawsuit Deramiocel FDA AdCom July 2026 already filed 10-Q 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-07-30 · 影响 weakens
Deramiocel疗效证据负面投票已在7月公开并已触发股价大跌,本条律所提醒不是新的强空催化。
检索:Capricor Therapeutics Deramiocel FDA advisory committee vote July 2026 stock reaction 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例研究不会改变本次AVOID;决定性因素是没有新增事实而非历史胜率。
方向:未使用外部先例,因为已确定本条是非增量律所提醒,历史先例不会改变不做结论。
涨幅量级:无可用于校准的新增事件幅度;核心负面已由7月FDA和AdCom事件完成定价。
形态:证券诉讼提醒通常依赖已发生股价损失招募原告,本条未构成新的价格锚。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 4,273 字
NEW YORK, Aug. 31, 2026 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.
So what: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Capricor class action, go to https://rosenlegal.com/cases/capricor-therapeutics-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, defendants made materially false and/or misleading statements and or failed to disclose that: (1) Capricor adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel, a cell therapy; (2) the FDA had not agreed to those changes before Capricor resubmitted the Deramiocel Biologics License Application (the "BLA"); (3) as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; (4) as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy; and (5) as a result of the foregoing, defendants' positive statements about Capricor's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Capricor class action, go to https://rosenlegal.com/cases/capricor-therapeutics-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.
So what: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Capricor class action, go to https://rosenlegal.com/cases/capricor-therapeutics-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, defendants made materially false and/or misleading statements and or failed to disclose that: (1) Capricor adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel, a cell therapy; (2) the FDA had not agreed to those changes before Capricor resubmitted the Deramiocel Biologics License Application (the "BLA"); (3) as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; (4) as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy; and (5) as a result of the foregoing, defendants' positive statements about Capricor's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Capricor class action, go to https://rosenlegal.com/cases/capricor-therapeutics-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。